Podcasts about moffitt cancer center

Computing resources are no longer just pieces of tech—they're scientific instruments. Moffitt Cancer Center's Jarett DeAngelis, director of scientific information technology, and Shane Corder, senior HPC engineer, join cohost Jessica StLouis, senior scientific consultant at BioTeam, to discuss new approaches changing access to HPC resources and how platforms like Open OnDemand are simplifying the HPC experience for those unfamiliar with the system. They also share their thoughts on the future of HPC resources, what the Moffitt Cancer Center is planning, and what they expect to see in the field in the coming years. Links from this episode:  Bio-IT World BioTeam Bio-IT World Europe Moffitt Cancer Center Bio-IT World's Trends from the Trenches podcast delivers your insider's look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders.

On this episode Justin records live in Tampa FL at the Moffitt Cancer Center for this special series during CancerX 2026. His first guests, from the Moffitt Center are Dr. Kamal Jethwani, VP Digital Ventures & CEO AccelerOnc, Dr. Nainesh Parikh, VP Chief Expansion & Partner Officer, and Dr. Patrick Hwu, President & CEO. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Dr. Michelle Moccia, DNP, ANP-BC, GS-C, an Adult Geriatric Nurse Practitioner, and Chair of GAPNA's Chapter Leadership Committee.  Dr. Moccia reflects on her 50-year nursing career, highlighting her pioneering work in geriatric care, including developing Michigan's first Level 1 accredited geriatric emergency department. She discusses community collaborations to improve emergency preparedness in nursing homes and initiatives to ensure patient-centered care through advanced directives and training. The conversation emphasizes compassionate, consistent care and practical strategies to better support older adults across healthcare settings.Dr. Michelle Moccia, DNP, ANP-BC, GS-C, is an Adult Geriatric Nurse Practitioner, in Livonia Michigan, and serves as GAPNA's Chapter Leadership Chair.  Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

In this episode, Dr. Cassandra Vonnes, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Dr. Kimberly Posey, the Coordinator of the Executive Nurse DNP Program and MSN Nursing Education Program at Texas Christian University, in Fort Worth, TX, and currently serves as GAPNA's President.  Dr. Posey shares her unconventional path from a technical career at IBM to discovering her passion for nursing and geriatric care. She discusses community-based initiatives, including a foot care clinic for unhoused older adults, and shares insights from her research on nurse practitioner job satisfaction and interprofessional education in long-term care. She also highlights her policy work on the Texas Nursing Facility Administrators Advisory Committee, emphasizing the importance of advocacy, mentorship, and advancing high-quality, compassionate care for older adults.Dr. Kimberly Posey, PhD, DNP, APRN, AGPCNP, GS-C, FAANP, is the Coordinator of the Executive Nurse DNP Program and MSN Nursing Education Program at Texas Christian University, in Fort Worth, TX, and currently serves as GAPNA's President.  Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

A cancer diagnosis can feel overwhelming - but patients are not powerless. In this episode, Dr. Nainesh Parikh of Moffitt Cancer Center explains how patients and families can better advocate for themselves, navigate complex healthcare systems, and get connected to the right care at the right time.

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with MJ Henderson, MS, RN, GNP-BC, a Gerontological Nursing Consultant and a Retired Assistant Professor at MGH Institute of Health Professions, in Boston Massachusetts.Together, they discuss GAPNA's evolution toward inclusivity across all advanced practice nursing roles, the importance of student engagement in professional organizations, and Ms. Henderson's continued commitment to supporting older adults through the Village to Village Network. Henderson shares her passion for gerontological nursing, lifelong learning, and community connection. MJ Henderson, MS, RN, GNP-BC, is a Gerontological Nursing Consultant and a Retired Assistant Professor at MGH Institute of Health Professions, in Boston Massachusetts.Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series. Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

La Dra. Isabel Matilde Chinchía, hematóloga y oncóloga clínica del Grupo de Linfomas de la ACHO en Colombia, y el Dr. José Sandoval, hematólogo oncólogo del Moffitt Cancer Center en Estados Unidos, presentan un análisis de los avances más relevantes del año 2025 en el manejo de los linfomas.POLARGOSTARGLOSUNMODatos del mundo real de epcoritamab/glofitamabMaterial exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud. Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso. Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados.

Prof Claire Harrison from Guy's and St Thomas' NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.CME information and select publications here.

In today's episode, the discussion features Jonathan R. Strosberg, MD, a professor and leader in the Neuroendocrine Tumor Division and the Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in Tampa, Florida, who reviewed the clinical implications of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide (ITM-11) for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), drawing on efficacy and safety findings from the phase 3 COMPETE trial (NCT03049189). 

In this follow-up episode,  Dr. Nikolaos Papadantonakis continues the conversation with Dr. Colin Vale from Winship Cancer Institute of Emory University and Dr. Nancy Luna Torres from Moffitt Cancer Center, diving deeper into advanced transplant topics. This episode is ideal for patients and families who want to understand the nuances of transplant care and post-transplant management.

Join host Dr. Nikolaos Papadantonakis as he welcomes Dr. Colin Vale from Winship Cancer Institute of Emory University and Dr. Nancy Luna Torres from Moffitt Cancer Center to discuss the fundamentals of allogeneic hematopoietic stem cell transplantation for MDS patients.  Our experts break down complex medical concepts into easy-to-understand language, helping patients make informed decisions about this important treatment option.

Dr. Olga Klinkova, Infectious Diseases Clinician at the Moffitt Cancer Center and Research Institute, presents a talk on Candida Infections. Dr. Klinkova begins by discussing the epidemiology of Candida. She then touches upon the importance of biofilms on the pathogenicity of Candida strains. Next, she breaks down the individual Candida species and highlights unique characteristics of each one. Following this, she presents several unique cases of human Candida infections and through the cases, highlights Candida auris, oropharyngeal candidiasis, esophageal disease, and candidemia. Lastly, she closes with information on hepatosplenic candidiasis.

In this episode, we sit down with Dr. Joseph Pidala from the Moffitt Cancer Center to discuss chronic graft-versus-host disease (GVHD), a complex condition affecting many stem cell transplant survivors. We focus on the latest prevention strategies, treatment innovations, and the critical role that clinical trials continue to play in advancing care.We begin with promising news around prevention. Dr. Pidala shares data from the BMT CTN 1703 trial, which compared conventional GVHD prevention to a newer approach using post-transplant cyclophosphamide (PTCy). This newer strategy significantly reduced the incidence of both acute and chronic GVHD, signaling a major step forward in preventing this debilitating condition.Despite advancements, many patients still experience chronic GVHD, which drives the need for new treatments. We explore several groundbreaking clinical trials that are rethinking traditional steroid-heavy treatment protocols. One study is testing Rezurock (Belumosudil) as a preemptive treatment during early symptoms, while another is investigating whether Jakafi (Ruxolitinib) can be used as a first-line treatment to reduce steroid reliance. These trials challenge old norms and aim to improve long-term outcomes.We also take a look at the four FDA-approved therapies currently available for steroid-refractory chronic GVHD: Ibrutinib, Jakafi, Rezurock, and the most recent addition, Axatilimab (Niktimvo). These drugs, each with different mechanisms and side effects, give patients and clinicians more flexibility than ever before. We touch on other widely used therapies like ECP (photopheresis), which, while not FDA-approved, remain an important part of care.Patient involvement is a key theme throughout. Dr. Pidala emphasizes that progress would be impossible without those who enroll in clinical trials, sharing inspiring examples of patients who benefited from early access to now-approved drugs. He encourages patients to advocate for themselves and speak up about symptoms, improvements, or quality of life changes. Patient-reported outcomes are becoming standard in trials, offering critical insight into treatment success from the patient's perspective.Dr. Pidala also highlights the importance of addressing GVHD holistically. Beyond core treatments, supportive care—including help with dry eyes, itching, joint mobility, pain, and mental health—is crucial to improving day-to-day life. He stresses that long-term recovery is possible and shares a moving story of a young woman with severe GVHD who, through persistent treatment, regained functionality and returned to a fulfilling life.We close with advice for patients: be proactive, informed, and open to trial participation. And when seeking information on trials, always start by asking your clinical team—they'll know what's available and suitable for your specific situation. Above all, Dr. Pidala leaves us with a message of hope—there's real progress being made, and the future looks brighter than ever.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 – Introduction to Dr. Joseph Pidala01:21 – New GVHD Prevention Approaches02:44 – Why Clinical Trials Matter03:22 – Challenging Steroid-Based Treatment Norms06:14 – Timeline for New Treatment Results07:02 – FDA-Approved Drugs for Chronic GVHD09:09 – Individualized Treatment Approaches10:69 – The Role of Patient-Reported Outcomes13:44 – Symptom Management and Supportive Care15:20 – Addressing Mental Health in GVHD17:30 – Inspirational Patient Story21:12 – Advice for GVHD Patients23:02 – How to Find Clinical Trials25:06 – Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On this episode Justin records live at HLTH25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week Justin talks to Michael Silverstein, Managing Partner of Healthcare IT & Life Sciences, DRI and Kamal Jethwani, MD, Co-Founder, Decimal.health and VP, Digital Ventures, Moffitt Cancer Center. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

On this episode Justin Barnes records live at HLTH25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week Justin talks to Nainesh Parikh, MD, MBA, VP, Chief Clinical Expansion & Partnerships Officer at Moffitt Cancer Center, and Rich Scarfo, President at HLTH, Inc. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

12 proven business models that separate successful products from failures!Product Manager Brian Orlando & Enterprise Business Agility Consultant Om Patel examine 12 real-world business models with real examples of the companies that employ them!Based on "The Art of Profitability" by Adrian Slywotzky (2002), this part-1-of-2 podcast covers:• Customer Solution Model (Palantir, SAP, Salesforce)• Product Pyramid (Apple, Tesla, GM)• Multi-Component Pricing (Uber, Coca-Cola)• Switchboard Platforms (Uber, Airbnb, eBay)• Time & Materials (Consulting firms)• Blockbuster Model (Pharma, Netflix)• Profit Multiplier (Microsoft, Disney)• Entrepreneurial Model• Specialist Model (Mayo Clinic, Agile Coaches)• Installed Base (Printers, Razors, K-Cups)• De Facto Standard (Windows, Adobe PDF)• Brand Model (Apple, Nike, BMW)Perfect for product managers, agile coaches, startup founders, and business leaders trying to understand which revenue model fits their product strategy.

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML). Join us as we delve into: • An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. • Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias. • Unique side effects associated with each TKI and strategies for dose optimization. • The importance of patient education and monitoring to ensure effective management of side effects. Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care! #CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

Gregorio Uglioni sits down with senior customer experience manager Patty Soltis to explore the intricate dynamics of convincing the C-suite to embrace customer experience initiatives. Patty shares invaluable insights on aligning CX efforts with business strategies, understanding executive priorities, and demonstrating the true value of CX to drive profitability. This episode is a must-listen for anyone looking to bridge the gap between customer experience and executive buy-in. About Patty Soltis Over three decades of experience, Patty has been a practitioner, consultant, and analyst in CX. She led dysfunctional organizations through change management to profitability. She found significant financial benefits with more profitable sales and lower expenses using the CX discipline. Using customer-centric business strategies, Patty created customer centric cultures, advised organizations to adopt CX, and analyzed CX best practices. Patty started her career listening to the voice of the employee, learning more about the customer elevating customer experiences. Patty serves as a senior customer experience manager at Upwork. Patty was a principal analyst – CX for eMarketer/Insider Intelligence and a patient experience consultant for Moffitt Cancer Center. She was a consultant for several years working with both small and enterprise organizations. Patty worked in retail for 27 years. She was a VP/GM for Neiman Marcus, Marshall Fields, and Lord & Taylor. Patty is a CCXP, CX-PRO and was named a CX Influencer by CX Network in 2024 and CX Scoop in 2023. She is an active member of the CXPA where she led the writing of the Book of Knowledge, launched the FL CXPA network, serves as a leader on the FL network and the Regional Council. Patty is a member of Horizon CX Board of Advisors. Resources  Upwork: https://www.upwork.com/ Please, hit the follow button and leave your feedback: Apple Podcast: https://www.cxgoalkeeper.com/apple Spotify: https://www.cxgoalkeeper.com/spotify Follow Gregorio Uglioni on Linkedin: https://www.linkedin.com/in/gregorio-uglioni/ Gregorio Uglioni is a seasoned transformation leader with over 15 years of experience shaping business and digital change, consistently delivering service excellence and measurable impact. As an Associate Partner at Forward, he is recognized for his strategic vision, operational expertise, and ability to drive sustainable growth. A respected keynote speaker and host of the well-known global podcast Business Transformation Pitch with the CX Goalkeeper, Gregorio energizes and inspires organizations worldwide with his customer-centric approach to innovation.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Part 2 - Neville James is joined by Paul Blair and Kurt Schindler as they host a big Halloween bash from October 29 to November 2 at Bungalows on the Bay, featuring live bands, a haunted house, friendly family events, trunk or treat. Fundraiser to benefit Moffitt Cancer Center in Florida.

Every high-performing business has one thing in common: reliability. Hospitals cannot afford mistakes. Neither can you. In this episode of Beyond The Claim, Vince Perri sits with Anay Moscu, PharmD, BCPS, BCOP, ACRP-CP, Director of Pharmacy for Outpatient Infusion Centers at Moffitt Cancer Center, to uncover the systems that literally save lives and show how you can use them to scale your company faster. What you will learn: • The Stop Error Stack: how hospitals eliminate million-dollar mistakes • Why every business needs independent checks and hard stops • The Empathy with Accountability formula for leading under pressure • How to design checklists people actually follow • AI tools hospitals use today that you can apply to your business Chapters: 00:00 Intro: Checklists That Save Lives 01:52 What Oncology Pharmacy Really Does 05:40 How Clinical Trials and Infusion Workflows Operate 09:28 The Stop Error Stack: Eliminating Mistakes 13:35 Clean Rooms, Barcoding, and Validation 17:10 Building Systems That People Actually Follow 21:22 Hiring For Detail And Team Fit 26:45 Balancing Empathy With Accountability 32:12 Getting Buy-In Across Teams 37:44 AI And Automation In Modern Pharmacy 42:55 Translating Hospital Systems To Business Growth 48:05 Life Advice: Be Present And Give Yourself Grace 52:00 Outro And Free Checklist Guest Contact Links

Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today's biotech macro headwinds and building companies that can translate breakthrough science into real patient impact. Dr. Duyk traces his journey from Harvard/Millennium/Exelixis operator to TPG investor and back to company creation, explaining how board dynamics, capital cycles, and policy shifts shape execution. They dig into why this cycle feels uniquely tough—patent cliffs, reimbursement uncertainty, NIH pressures—and who funds innovation in the meantime. Duyk outlines root causes of R&D inefficiency (misaligned capital vs. 20-year timelines, shaky preclinical predictability, costly trials, underused real-world data) and makes the case for rebuilding public trust and STEM education. Then, a deep dive on Grove Biopharma: precision polymer science that creates antibody-like, fully synthetic, cell-permeable protein mimetics to tackle historically “intractable” intracellular protein–protein interactions. Duyk shares design principles, why modular/orthogonal chemistry matters, predictable pharmacology, and lessons from fundraising and board management—plus why he's helping grow a Chicago-centered biotech ecosystem. Biography: Geoffrey M. Duyk, M.D., Ph.D. is the Chief Executive Officer of Grove Biopharma. Dr. Duyk has spent 30 years in the biotechnology industry as an entrepreneur, executive, and investor. Most recently, he was the Managing Partner at Circularis Partners, an investment firm he co-founded, focused on advancing the circular economy and promoting sustainability. Prior to that, Dr. Duyk was Managing Director and Partner at TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology. Before joining TPG, Dr. Duyk served as a board member and President of R&D at Exelixis and was one of the founding scientific staff members at Millennium Pharmaceuticals, where he served as Vice President of Genomics. Earlier in his career, Dr. Duyk was an Assistant Professor in the Department of Genetics at Harvard Medical School (HMS) and an Assistant Investigator at the Howard Hughes Medical Institute (HHMI). While at HMS, he served as a co–principal investigator in the Cooperative Human Linkage Center, which was funded by the National Institutes of Health (NIH). Dr. Duyk is a trustee of Case Western Reserve University, where he serves on the executive committee. He previously served on the Board of Trustees of Wesleyan University and the Board of Directors of the Moffitt Cancer Center. He currently serves on the IR&E (Institutional Research and Evaluation) Committee at Moffitt, a key component of its External Advisory Committee (EAC). He was also a member of the Board of Directors of the American Society of Human Genetics (ASHG), and served as its treasurer. He is a member of the Life Sciences Advisory Board at Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Laboratory (DOE). Dr. Duyk previously served on the board of the Jackson Laboratory and on numerous NIH advisory committees. He is currently a Senior Advisor at Qiming Venture Partners (USA) and serves on the boards of Enno DC, Oobli, and Melanyze Dr. Duyk earned both his M.D. and Ph.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a Lucille P. Markey Fellow and an HHMI postdoctoral fellow. He is a fellow of the American Association for the Advancement of Science.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Kidney cancer management is evolving. How are experts adapting? In this installment of BackTable Tumor Board, Dr. Brandon Manley (Urologic Oncology, Moffitt Cancer Center), Dr. Raquibul Hannan (Radiation Oncology, UT Southwestern), and Dr. Rana McKay (Medical Oncology, UC San Diego) join guest host Mark Ball (Urologic Oncology, National Cancer Institute) to share their multidisciplinary perspectives on challenging, real-world kidney cancer cases.---This podcast is supported by:Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1---SYNPOSISThe conversation covers diagnostic dilemmas, navigating the treatment options of surgery, systemic therapy, and radiation, and the importance of a multidisciplinary approach. Through detailed case reviews, the panel highlights practical pearls, emerging clinical trials, and collaborative approaches that exemplify modern kidney cancer care.---TIMESTAMPS0:00 - Introduction02:20 - Case 1 (Incidental Renal Mass)16:52 - Case 2 (Bilateral Renal Masses)37:22 - Case 3 (Locally Advanced Renal Mass)56:34 - Case 4 (Symptomatic, Metastatic Disease)01:14:00 - Final Takeaways

In today's episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.   In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with myelofibrosis who have mutations in JAK2, CALR, or MPL; the crucial roles of the JAK1, JAK2, and IRAK1 pathways in disease progression; the importance of considering JAK inhibition in eligible patients; and the challenges associated with managing cytopenic myelofibrosis.

In this episode, we explore Carthera, a French biotech company developing novel ultrasound-based technologies to improve drug delivery to the brain. Based in Paris and spun out from academic research, Carthera is best known for its implantable device, SonoCloud, which uses low-intensity pulsed ultrasound to temporarily open the blood-brain barrier. This allows for increased drug penetration into brain tumors, addressing one of the major challenges in treating diseases like glioblastoma. This episode features leadership and key collaborators from Carthera, including CEO Frédéric Sottilini, who shares how his background in therapeutic ultrasound and medical device development helped guide the company's path from concept to clinical trials. We are also joined by Professor Alexandre Carpentier, MD, PhD, the neurosurgeon who founded Carthera, and Michael Vogelbaum, MD, PhD, Chief of Neurosurgery at Moffitt Cancer Center, who offers his perspective as a clinical investigator working with the company's technology. This episode offers insight into the intersection of engineering, neurosurgery, and translational research, and the collaborative effort required to develop new treatment tools for brain tumor patients. Learn more at https://carthera.eu/ This episode is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health or treatment plan.

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

Dr Jonathan Strosberg from Moffitt Cancer Center in Tampa, Florida, discusses recent updates on available and novel treatment strategies for extrapulmonary neuroendocrine carcinoma. CME information and select publications here.

In today's episode, supported by Autolus, we spoke with Aaron Logan, MD, PhD, and Bijal Shah, MD, MS, about the evolving use of obecabtagene autoleucel (obe-cel; Aucatzyl) in the relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treatment paradigm. Dr Logan is an associate professor of clinical medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) School of Medicine, as well as a member of the UCSF Helen Diller Family Comprehensive Cancer Center. Dr Shah is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.  In our conversation, Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm, how the use of this agent might expand going forward, and what the future looks like for the broader CAR T-cell therapy development field in ALL. 

This episode features Joanna Weiss, Executive Vice President and CFO at Moffitt Cancer Center, who shares her journey through finance and revenue cycle leadership. She discusses key priorities including financial stabilization, strategic growth, AI-driven automation, and how the CFO role is evolving to support long-term innovation and patient-centered care.

Terms like hospice and palliative care can instantly make us think of worst case scenarios, but whether you are a patient or a caregiver, they should be considered a normal part of the experience offered by experts in Supportive Care Medicine. Treating a patient is not just about killing the cancer, but doing everything you can to improve their quality of life, a subject that Dr. Saima Rashid is familiar with as a specialist in palliative care, and Parmvir as a caregiver to her sister Sukhneil. Join us to learn more about how and when to request services, and the benefits that they offer. Find out about the work being done by Moffitt's Department of Supportive Care Medicine and how they can help you: https://www.moffitt.org/treatments/supportive-care-medicine/ Learn more about our guests: Dr. Saima Rashid: https://www.moffitt.org/providers/saima-rashid/ Dr. Parmvir Bahia: parmvir.com Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach and Engagement at Moffitt Cancer Center and Artha Science Media. Follow COE: https://www.linkedin.com/in/coee-at-mcc Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

Cancer is a profoundly disabling illness, whether that is due to side effects from the life-saving treatments or the disease itself. Understandably then, patients need constant and vital support in the form of caregivers, but who do we consider to be a caregiver, and what does their role involve? In this episode we discuss the essential role of caregivers, who qualifies as a caregiver, and the responsibilities they take on. We also address an important question: who looks after the caregivers when they themselves are impacted? Join us as we uncover the challenges and rewards of caregiving in the context of cancer, and highlight the importance of support for those who give so much to others. Learn more about our guests: Mr. Travis Coy: https://www.linkedin.com/in/travis-j-coy Dr. Parmvir Bahia: parmvir.com Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach, Engagement, and Equity at Moffitt Cancer Center and Artha Science Media. Follow COEE: https://www.linkedin.com/in/coee-at-mcc Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dived deep into the world of myeloproliferative neoplasms (MPNs), focusing specifically on polycythemia vera (PV) and essential thrombocythemia (ET). They are joined by Dr. Andrew Kuykendall, a hematologist from Moffitt Cancer Center, who shared his expertise on the latest treatment paradigms and risk stratification strategies for these conditions. Key topics discussed included: • The importance of ruling out secondary causes of erythrocytosis in PV patients. • The role of JAK2 mutation testing and EPO levels in diagnosis of PV. • Treatment options for PV, including phlebotomy, hydroxyurea, and interferon, as well as the emerging role of ruxolitinib. • Risk stratification in ET and the significance of driver mutations like JAK2, CALR, and MPL. • The management of acquired von Willebrand disease in patients with high platelet counts. • Insights from Dr. Kuykendall's recent ASCO plenary presentation on the VERIFY Study and the potential of resveratide in PV treatment. Join us for an informative discussion that highlights the evolving landscape of MPN management and the importance of individualized treatment plans.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our other hematology episodes for more insights into challenging cases and treatment algorithms!  

On this episode you'll hear from caregivers and advocates about how they face this challenge. Our guests are Rachel Piltch-Loeb, author of The Millennial Caregiver: Caring for Loved Ones in the Busiest Years of Your Life. Viviam Sifontes, research educator at Moffit Cancer Center Lauren Klinger, a Wesley Chapel resident and writer. She's been a caregiver and is author of the “Learn from My Mistakes” Substack. Thanks to our partners in developing this show - Moffitt Cancer Center in Tampa and the Alzheimer's Association, Florida region. This Caregiving project was funded by a grant from WETA and Vu Haus. It's part of a new documentary and national engagement campaign on the state and stakes of providing care in America. A feature-length documentary and accompanying short films are available on PBS.org and at Well Beings. 

Dr. Robert Castro, Infectious Diseases Clinician at the Moffitt Cancer Center and Research Institute, presents this review on infections associated with vector-borne and zoonotic exposures. Dr. Castro begins by discussing vector -borne infections, dividing them into mosquito-borne and tick-borne diseases. Syndromes discussed include Dengue, Chikyunguna, West Nile Virus, and Japanese Encephalitis. Next, Zoonotic infections such as Rabies Virus, Hantavirus, Orf virus, and B virus are covered. Dr. Castro closes by discussing vector control strategies.

ABOUT THIS EPISODENeuroendocrine cancer care typically involves a multidisciplinary team which sometimes involves an Advanced Practice Provider (APP). In this episode, Moffitt Physician Assistant Tiffany Valone clarifies the role of an APP in neuroendocrine cancer.TOP TEN QUESTIONS What is a NP/PA/APP? -Are you a doctor? How are you different from or similar to a doctor? - How is your role similar to or different from a nurse practitioner? How did you enter the neuroendocrine cancer or NET world? How did you learn about neuroendocrine cancer? Could you be considered a NET expert? What is your role in the neuroendocrine cancer world? What is your role with your medical team? If I go to your institution to see a neuroendocrine cancer expert, how is it determined which provider I will see?If I see you (or another NP/PA), would I also see a doctor? If yes, when/how? If not, why/why not and how does this work? What does a “team approach” mean?Who goes over scan results? Is this something you can do?Who orders my scans and treatments?If I have a question or concern, who do I communicate with and what's the best way to communicate?How are your recommendations communicated with someone's local oncologist?What advice do you have for patients when they receive differing opinions?*Bonus: How do you continue to learn and keep up to date with neuroendocrine cancer? What recommendations would you have for patients who would like to encourage their local oncologists or APPs to learn about neuroendocrine cancer?ABOUT TIFFANY VALONETiffany Valone is a Physician Assistant and Manager of the GI and Senior Adult Advanced Practice Providers at Moffitt Cancer Center in Tampa, FL. She started her career at Moffitt in 2006 in GI medical oncology focusing on treating patients with colorectal and pancreaticobiliary cancers. A few years into her career she joined Dr. Jonathan Strosberg to help with his growing neuroendocrine practice.  For the past 16 years she has been an integral provider within this multidisciplinary team.  She was awarded Moffitt's Advanced Practice Provider of the Year in 2012 and the North American Neuroendocrine Tumor Society's AHP/APP of the Year in 2024. She is also a member of Moffitt's APP Professional Clinical Ladder Executive Committee and spearheads Moffitt's APP Grand Rounds lecture series. She has a passion for teaching and mentoring new providers in the NET field. She has given presentations on NETs and other GI malignancies at both state and national conferences. In her spare time, she enjoys traveling with her husband and three children or relaxing at the beach.  For more information, visit https://www.ncf.net/podcast/46For more information, visit NCF.net.

This week, Steph & Ash keep the Tampa Bay Tech PoweredUp series rolling with a fun and insightful chat with Doug Fee, Chief Information Security Officer at Moffitt Cancer Center. We explore the complex tech challenges facing the healthcare world, including the vital role cybersecurity plays in protecting patients and their data. Doug also breaks […] The post Bold Moves in Healthcare Tech with Moffitt’s CISO appeared first on Radio Influence.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

June is recognized in the US as Caribbean-American Heritage Month. So what better time to say Sante! or Cheers! to recognize the important achievements of researchers working to support members of the Caribbean community. We speak with Dr. Dorothie Durosier Mertilus about how important it is it literally be able to speak someone's language; in her case French or Haitian Creole. We hear from from Dr. Clement Gwede, the scientist whose lab is out in the community. Coming at gaps in care from different angles means that patients can be supported in meaningful ways, to offer them the best outcomes. Learn more about our guests: Dr. Dorothie Durosier Mertilus, and Dr. Clement Gwede. Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach, and Engagement at Moffitt Cancer Center and Artha Science Media. Follow COE: https://www.linkedin.com/in/coee-at-mcc Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

Robin Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Robin Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robin Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

My team at Moffitt Cancer Center helped save my life and I'm forever grateful for their brilliance, dedication, and friendship over the past 6+ years. This is a repost of the episode I did with them last year.  Being a guest on the PEP Talks podcast for providers and staff at Moffitt was an honor, a privilege, and a labor of love. Moffitt is an amazing place filled with amazing people dedicated to curing cancer.Side note: I know I've been off the radar for a couple of years -- life's been challenging and busy and full of good things. Meanwhile, in addition to my full-time job, I'm writing a book about dealing with cancer, developing public speaking opportunities, and working on arrangements for the apartment we just bought in Italy. It's been a lifelong dream and we're so excited! I'll do an episode about this in the not-to-distant-future, so you can come along for that process, as well. It's all part of the "etc." in "Life, Cancer, Etc."Keywords: Moffitt, H. Lee Moffitt Cancer Center, cancer diagnosis, sarcoma, cancerNote: I'm not a medical professional. Everyone in these podcasts is sharing their own experiences.You can also find some episodes on our YouTube channel: https://www.youtube.com/c/LifeCancerEtcYou can also find some episodes on our YouTube channel: https://www.youtube.com/c/LifeCancerEtc

Send us a textIn this episode of the 'Midlife with Courage' podcast, host Kim welcomes the magical Kimmie Sue Hall. They discuss Kimmie Sue's life in Orlando, Florida, her courageous journey helping a friend overcome alcoholism, her retirement from a 30-year career with Disney, and the personal trials faced when her son battled cancer. She also shares some glimpses into her role as the wife of a rockstar and how the unexpected end of REO Speedwagon changed how she saw her future playing out. The episode highlights themes of courage, family, and authenticity while sharing inspiring anecdotes about making dreams come true at Disney and providing support during challenging times. Kimmie Sue also shares plans for a meaningful upcoming concert and her son's involvement in cancer awareness and support. 00:00 Introduction to Midlife with Courage00:21 Meet Kimmie Sue Hall01:29 A Courageous Conversation04:46 Kimmie Sue's Magical Career at Disney12:49 Tommy's Battle with Cancer17:58 Facing the Unthinkable: A Mother's Strength18:44 Raising Awareness: Testicular Cancer19:38 Miracles and Mentorship20:18 Foundations and Family Support23:42 A New Chapter: College and Music26:02 A Farewell Concert for a Cause33:11 Final Thoughts and Messages"Courage is a very contagious thing." Dr. Philippe Spiess of Moffitt Cancer Center in Tampa Florida. If you would like to support the Moffitt Cancer Center through a donation, please go to this link: https://fundraise.moffitt.org/campaign/651751/donateSupport the showKim Benoy is a retired RN, Certified Aromatherapist, wife and mom who is passionate about inspiring and encouraging women over 40. She wants you to see your own beauty, value and worth through sharing stories of other women just like you.Would you like to get a "sneak" listen to each podcast? Subscribe to my website to get my weekly inspirational message and a link to that week's podcast a day ahead of everyone else! Just click the link below to get on the list! SUBSCRIBE WEBSITEFACEBOOK

Research is so critical to the field of surgery worldwide. But how does the world of academic surgery compare in the UK? Join BTK fellow Jon Williams and ASGBI partner Jared Wohlgemut  for another installment of our BTK/ASGBI collaborative series where we take a deep dive investigating the many facets of surgical research–everything from getting started, funding, collaboration, mentorship, and sage advice from two incredibly successful academic surgeons. Professor Susan Moug represents the UK while Dr. Lesly Dossett represents the US in this excellent episode for any trainee or surgeon who is academically-inclined. After listening, you get to decide–who does it better?? UK or US? Professor Moug is an Honorary Professor at the University of Glasgow, Scotland. She is a Consultant Colorectal and Robotic surgeon at Golden Jubilee National University Hospital in Clydebank, and at the Royal Alexandra Hospital in Paisley, Scotland. She is also the Director of Research for the Association of Surgeons of Great Britain and Ireland since 2021, and the Surgical Specialty Lead for Colorectal Research at the Royal College of Surgeons of England. She has been awarded a Senior Fellowship from the Chief Scientist Office of the Scottish Government, and was the chief investigator for the Emergency Laparotomy in Frailty multicentre study, and the No-Laps follow-on study. Essentially, she is one of the leading researchers in emergency surgery in the UK, having been awarded over 1 million in grant funding for this under-researched and underfunded area. Dr. Dossett is an associate professor and surgical oncologist at the University of Michigan. After completing her undergraduate degree at Western Kentucky University, She completed both medical school and her general surgery residency at Vanderbilt University in Nashville, TN, during which she obtained an Agency for Healthcare Research and Quality training grant as well as a Masters in Public Health during research time. Following residency, she served as an active duty staff surgeon in the US Navy for several years before pursuing surgical oncology fellowship training at Moffitt Cancer Center. In 2016 she came on to University of Michigan as faculty and has since held numerous academic leadership roles both institutionally and nationally, including vice chair for faculty development, chief of the division of surgical oncology, and president of the Surgical Outcomes Club. Dr. Dossett has an impressive portfolio of research work focusing on implementation and de-implementation of comprehensive cancer care, which is funded through multiple NIH grants.  If you enjoyed this episode, stay tuned for more upcoming BTK/ASGBI collaborative content. If you have any questions or comments, please feel free to reach out to us at hello@behindtheknife.org.  ***SPECIALTY TEAM APPLICATION LINK: https://docs.google.com/forms/d/e/1FAIpQLSdX2a_zsiyaz-NwxKuUUa5cUFolWhOw3945ZRFoRcJR1wjZ4w/viewform?usp=sharing